Explore

ReutersReuters
Novo Nordisk open to direct New York listing, CEO Doustdar tells FT

Novo Nordisk open to direct New York listing, CEO Doustdar tells FT

Sept 23 (Reuters) - Novo Nordisk is open to considering a direct New York Stock Exchange listing, replacing the American depositary receipts through which US investors currently trade its shares, CEO Mike Doustdar told the Financial Times in an interview published on Wednesday.
TheStreetTheStreet
Novo Nordisk CEO opens the door to major move for U.S. investors

Novo Nordisk CEO opens the door to major move for U.S. investors

The U.S. now accounts for more than half of Novo Nordisk’s revenue.
Arizona RepublicArizona Republic
Could GLP‑1 drugs be causing blindness? Arizona lawsuits are growing

Could GLP‑1 drugs be causing blindness? Arizona lawsuits are growing

Arizonans trusted GLP-1 drugs to lose weight. Now, a growing number of lawsuits claim the medications may be linked to blindness.
Rapid ReadRapid Read
U.S. Lawsuits Allege Vision Loss from GLP-1 Drugs Ozempic and Wegovy

U.S. Lawsuits Allege Vision Loss from GLP-1 Drugs Ozempic and Wegovy

A growing number of lawsuits in the U.S. are alleging that GLP-1 class drugs, including Ozempic and Wegovy, are causing non-arteritic anterior ischaemic optic neuropathy (NAION), a condition leading to sudden, potentially irreversible vision loss. Over 90 lawsuits have been filed against Novo Nordisk in New Jersey, with additional cases in federal court in Pennsylvania, targeting manufacturers like Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound). Plaintiffs claim that these manufacturers failed to adequately warn patients about the risk of NAION. NAION, often described as an 'eye stroke,' results from reduced blood supply to the optic nerve and typically affects one eye. While the U.S. Food and Drug Administration (FDA) is investigating the possible link, it has not yet added a specific NAION warning to GLP-1 drug labels. Manufacturers dispute these allegations, with Novo Nordisk stating its research found no increased risk.
USA TodayUSA Today
What to know about ibogaine, the drug Presley Gerber used for treatment months before death

What to know about ibogaine, the drug Presley Gerber used for treatment months before death

Presley Gerber shared his experience with ibogaine months before his death. What is the psychedelic compound? Why is it used in addiction treatment?
ReutersReuters
Japan's steep yield curve opens 'reverse carry' trade opportunity, Eastspring says

Japan's steep yield curve opens 'reverse carry' trade opportunity, Eastspring says

By Ankika Biswas and Divya Chowdhury Sept 22 - A rise in Japanese bond yields is creating a "reverse carry" opportunity for overseas investors as Bank of Japan interest-rate hikes make the traditional yen-funded carry trade less compelling, Rong Ren Goh, fixed income portfolio manager at Eastspring
ReutersReuters
US FDA advisers endorse Grail cancer test's benefits in key vote

US FDA advisers endorse Grail cancer test's benefits in key vote

By Padmanabhan Ananthan and Kamal Choudhury Sept 23 (Reuters) - A panel of outside experts advising the US FDA said on Wednesday the benefits of Grail's blood-based cancer detection test outweigh its risks, paving the way for a potential landmark approval in cancer screening.
ReutersReuters
Novo CEO says pills could capture 50% of weight-loss market by 2030

Novo CEO says pills could capture 50% of weight-loss market by 2030

By Patrick Wingrove LONDON, Sept 22 - Weight-loss pills could capture as much as half of the global obesity drug market by 2030, Novo Nordisk's chief executive told Reuters on Tuesday, as the Danish drugmaker positions itself for a shift away from weekly injections.
ReutersReuters
Dollar choppy as investors weigh oil drop against Fed rate path

Dollar choppy as investors weigh oil drop against Fed rate path

By Chuck Mikolajczak Sept 22 (Reuters) - The dollar was slightly higher on Tuesday, but off a two-month high hit earlier in the day as investors weighed another decline in oil prices against the possibility of more rate hikes from the Federal Reserve. 
ReutersReuters
Explainer-Ban on US diesel exports would hurt, not help fuel markets, analysts say

Explainer-Ban on US diesel exports would hurt, not help fuel markets, analysts say

By Arathy Somasekhar and Liz Hampton HOUSTON, Sept 22 (Reuters) - US President Donald Trump on Tuesday said he backed the idea of a diesel export ban as a way to lower prices that have hit record highs due to a global supply shortage.
ReutersReuters
Oura targets $15.62 billion valuation in US IPO, setting stage for fall listings

Oura targets $15.62 billion valuation in US IPO, setting stage for fall listings

Sept 21 (Reuters) - Smart ring maker Oura is targeting a fully diluted valuation of $15.62 billion in its US initial public offering, as the fall listing window looks to kick back into action after a subdued start marked by market volatility.
ReutersReuters
Grail rallies as FDA staff flags no major concerns for multi-cancer test

Grail rallies as FDA staff flags no major concerns for multi-cancer test

By Christy Santhosh and Padmanabhan Ananthan Sept 21 (Reuters) - The US FDA's staff reviewers did not raise major concerns about the accuracy and safety of Grail's blood test designed to detect more than 50 cancers, sending the company's shares soaring 35% on Monday.